|Videos|February 20, 2023
Retreatment with a BCMA-Targeting Bispecific for R/R MM
Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.
Advertisement
Episodes in this series
Advertisement
Related to this article
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5